Get the Stockscreener App
2.99
0.33%
-0.010
Eledon Pharmaceuticals Inc stock is traded at $2.99, with a volume of 143.75K.
It is down -0.33% in the last 24 hours and down -17.63% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$3.00
Open:
$3.06
24h Volume:
143.75K
Relative Volume:
0.59
Market Cap:
$178.45M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.6704
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+5.65%
1M Performance:
-17.63%
6M Performance:
+6.41%
1Y Performance:
+90.45%
1-Day Range:
$2.925
$3.12
1-Week Range:
$2.76
$3.2089
52-Week Range:
$1.55
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.99 | 178.45M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Eledon Pharmaceuticals appoints Deloitte as new auditor By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals appoints Deloitte as new auditor - Investing.com
Charles Schwab Investment Management Inc. Purchases 15,000 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Virtu Financial LLC Takes $82,000 Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Is Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5? - Yahoo Finance
Equities Analysts Set Expectations for ELDN FY2025 Earnings - Defense World
Research Analysts Set Expectations for ELDN FY2025 Earnings - Defense World
What is Leerink Partnrs’ Forecast for ELDN Q1 Earnings? - Defense World
Eledon Pharmaceuticals Reports 2024 Financial Results and Clinical Advances - MSN
We're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash Wisely - Yahoo
10 Hot Biotech Stocks Under $5 - Insider Monkey
Eledon Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Eledon Pharmaceuticals Inc. (ELDN) reports earnings - Quartz
Eledon Pharmaceuticals FY Operating Expenses USD 70.577 Million -March 20, 2025 at 04:48 pm EDT - Marketscreener.com
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results - The Manila Times
Eledon Achieves Historic Transplant Milestones as Cash Position Hits $140M - StockTitan
Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday - Defense World
Institutional investors in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) see US$25m decrease in market cap last week, although long-term gains have benefitted them. - Simply Wall St
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - GlobeNewswire
When Can You Hear Eledon's Latest Strategic Updates? Key Conference Appearance Scheduled - StockTitan
Eledon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Eledon Touts Tegoprubart Used in Pig Kidney Transplant - Orange County Business Journal
Before You Invest, Make Sure You Check This Eledon Pharmaceuticals Inc (NASDAQ: ELDN) Analysis - Stocks Register
Leerink Partnrs Has Pessimistic Outlook of ELDN Q4 Earnings - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for ELDN Earnings - Armenian Reporter
Eledon's tegoprubart used in second pig-to-human kidney transplant - MSN
Leerink Partnrs Issues Negative Outlook for ELDN Earnings - Defense World
Eledon's tegoprubart used in second pig-to-human kidney transplant By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key - GlobeNewswire
Eledon announces tegoprubart use in transplant of pig kidney into human - TipRanks
Revolutionary Xenotransplant Success: Eledon Drug Enables Patient Freedom from Dialysis - StockTitan
FY2029 Earnings Estimate for ELDN Issued By Leerink Partnrs - Armenian Reporter
Eledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Eledon CEO to Reveal Latest Biotech Developments at Major Guggenheim Conference - StockTitan
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business - Seeking Alpha
Guggenheim Initiates Eledon Pharmaceuticals at Buy With $9 Price Target -January 28, 2025 at 07:34 am EST - Marketscreener.com
Inspire Investing LLC Invests $802,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Midday Stock Roundup: FivePoint Holdings Jumps 36% - Orange County Business Journal
Cantor Fitzgerald Comments on ELDN FY2025 Earnings - Defense World
Kidney Transplant Rejection Market Expected to Experience - openPR
Cantor Fitzgerald Weighs in on ELDN FY2025 Earnings - MarketBeat
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):